GRI Bio, Inc. (GRI)
NASDAQ: GRI · Real-Time Price · USD
0.632
-0.025 (-3.76%)
At close: Jan 31, 2025, 4:00 PM
0.664
+0.032 (5.13%)
After-hours: Jan 31, 2025, 7:14 PM EST
GRI Bio Employees
GRI Bio had 4 employees as of December 31, 2023. The number of employees increased by 3 or 300.00% compared to the previous year.
Employees
4
Change (1Y)
3
Growth (1Y)
300.00%
Revenue / Employee
n/a
Profits / Employee
-$2,065,750
Market Cap
5.65M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 4 | 3 | 300.00% |
| Dec 31, 2022 | 1 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
GRI News
- 5 weeks ago - GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds - GlobeNewsWire
- 2 months ago - GRI Bio to Participate in the Virtual Investor Closing Bell Series - GlobeNewsWire
- 2 months ago - GRI Bio Showcases GRI-0621's Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF) - GlobeNewsWire
- 2 months ago - GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis - GlobeNewsWire
- 3 months ago - GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024 - GlobeNewsWire
- 3 months ago - GRI Bio Announces Exercise of Warrants - GlobeNewsWire
- 3 months ago - GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621's Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF) - GlobeNewsWire
- 4 months ago - GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions - GlobeNewsWire